In 2013, a report by M. Ferwana et al. titled “Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.” was published in Diabetes Medicine that sought to evaluate the connection between the diabetes drug Actos and new-onset bladder cancer.
Living up to its name, this report reviewed data from six previous studies including a total of 215,142 Actos patients. The team writes “The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09-1.39; I(2) = 0%) compared with control groups.” (For clarity, “pioglitazone” is the chemical name for Actos.) What this data means is that patients using Actos were found to face a risk for bladder cancer elevated by 23%.
Unfortunately, the manufacturer of Actos failed to make this risk clear to users, and many people taking Actos developed bladder cancer unaware that the medication they used could have such terrible results. As a result of this, a number of Actos lawsuits have been filed seeking compensation from the manufacturer for the undue injuries of Actos patients.
If you or a loved one used Actos and suffered bladder cancer as a result, you too may be entitled to significant financial compensation. For a free, no-obligation case consultation, contact our team of Actos lawyers at the information provided below. We have the skills, resources, and experience required to win the justice you deserve. Call today and see how we can help.
(855) 452 – 5529